SalaryGuide
AboutPricingFor Employers

Marketing jobs

22 marketing jobs

Nuvation Bio logo
5 months ago

Senior Manager, Corporate Communications and Patient Advocacy

Nuvation Bio

New York, USA (On-site)Full time
Nuvation Bio logo
5 months ago

Senior Manager, Corporate Communications and Patient Advocacy

Nuvation Bio

Boston, MA (Remote)Full time
Previous
12
Next

Find marketing roles you could actually win

22 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media

Find marketing roles you could actually win

22 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media
22 jobs
Nuvation Bio logo

Senior Manager, Corporate Communications and Patient Advocacy

Nuvation Bio

New York, USA (On-site)

In-houseFull-timeSenior level5+ years exp.
5 months ago
Nuvation Bio logo

Senior Manager, Corporate Communications and Patient Advocacy

Nuvation Bio

Boston, MA (Remote)

In-houseFull-timeSenior level5+ years exp.
5 months ago
Previous12
Nuvation Bio logo
Nuvation Bio

Senior Manager, Corporate Communications and Patient Advocacy

New York, USA (On-site)

Salary Not AvailableSenior Level5+ years expFull time

Posted 5 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive biotech corporate communications and patient advocacy for Nuvation Bio, shaping messaging, media relations, and stakeholder engagement at scale.

  • Own media relations, digital campaigns, and patient advocacy projects to influence external perception and internal alignment.
  • Must-have: 5–7+ years in biotech/pharma corporate comms with public-company or agency experience.
  • Standout: Cross-functional collaboration and ability to translate complex science for diverse audiences.

Job Description

Responsibilities

  • Support engagement of key advocacy stakeholders, which could include: patients, caregivers, healthcare providers, and advocacy groups for engagement and collaboration based on mutual goals.
  • Develop, management, and maintenance of strategic corporate and PR communication materials, including press releases, presentations, Q&As, digital content, internal communications and more.
  • Support critical thought leadership efforts, to include short- and long-form content across platforms and audiences.
  • Develop compelling, authentic, and consistent messaging related to Nuvation Bio’s strategies, initiatives, pipeline, and performance. Ensure that all communications incorporate Best Practices and comply with pertinent SEC rules and FD regulations.
  • Work collaboratively with the Corporate Communications and Patient Advocacy team, as well as with other functional leadership and related agencies, to ensure consistent messaging for external/internal stakeholders, maximizing efficient use of resources
  • Own specific workstreams that support external and internal communications initiatives and patient advocacy engagement, including media relations, digital and social media campaigns, patient ambassador relationships and patient advocacy related projects.
  • Support the crafting of regular progress reports and presentations for key stakeholders, including the executive committee and cross-functional team, to provide updates on program performance and milestones.
  • Maintain pulse on disease-area landscapes from public sentiment, competitor positioning and advocacy-related efforts.

Requirements

  • Bachelor’s degree and a minimum of 5-7+ years of experience working in the biotech/pharmaceutical industry, with direct experience designing and executing corporate communications within a publicly traded company and/or in an agency setting.
  • Proven ability to speak the language of a pharmaceutical/biotech company and break down complex scientific concepts for both internal and external audiences.
  • Demonstrated track record of conducting successful, proactive communications efforts that employ creativity and use of a variety of tools, forums, media and metrics.
  • Experience developing thought leadership content for the company across various audiences and ability to pivot based content based on audience.
  • Understanding of the advocacy landscape and core engagement principles / best practices.
  • Trusted for flawless execution of proactive and reactive initiatives.
  • Maintains strong relationships with healthcare reporters, and industry media.
  • Knowledge of up-to-date compliance, legal, regulatory and other issues that impact communications and can apply them, accordingly, including knowledge of SEC and disclosure requirements.
  • Strategic agility, able to balance proactive/planning with reactive elements of the position. Thrives in the opportunity to support the full spectrum of biotech communications and patient advocacy needs, from internal communications efforts to medical meetings to thought leadership, and can successfully toggle as needs arise.
  • Dynamic, team player with excellent organizational, interpersonal, and influence skills. Experience working with agency partners. Demonstrates leadership abilities with room to grow into management as function evolves.
  • Enthusiastic about Nuvation Bio’s vision and mission and endorse and promote our values.

Preferred

  • Experience working with agency partners.
  • Leadership potential with room to grow into management as function evolves.
  • Enthusiastic about Nuvation Bio’s vision and mission and endorse and promote our values.

Benefits

  • Competitive Base Salary, Bonus, and Equity Plans
  • Unlimited Vacation and 10 Sick Days Annually
  • Excellent Medical, Dental, and Vision Coverage
  • 401K with Company Matching
  • and much more!
Nuvation Bio logo

Nuvation Bio

4.7 Glassdoor

Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai.

Founded in 2018
New York, New York, USA
220 employees (17 in marketing)
www.nuvationbio.com
100% recommend to a friend
100% CEO approval

Traffic Signals

Monthly Visitors
21.8K
Monthly Google Ads Budget
$13.2K
Traffic Source Mix
Search
39%
Direct
44%
Referral
5.1%
Social
9.8%
Paid
2%

Headcount Trend

Current headcount: ~220

Marketing Team

Marketing Team Size
16 (7% of company)

Funding

Total Funding
$927M
Last Raise
$150M
Post IPO Debt, 1 years ago

Funding History

  • Mar 2025
    Post IPO Debt • $150M
  • Feb 2021
    Post IPO Equity • $502M
  • Oct 2019
    Series A • $275M

Recent News

Citizens Maintains Nuvation Bio (NUVB) Market Outperform Recommendation
Nov 21, 2025 • Nasdaq
Nuvation Bio Surges On Ibtrozi Momentum And B. Riley Buy Rating (NYSE:NUVB)
Nov 20, 2025 • Seeking Alpha
B. Riley Securities Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation
Nov 20, 2025 • Nasdaq
Nuvation Bio stock hits 52-week high at $5.57
Nov 19, 2025 • Investing.com
Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress
Nov 19, 2025 • Finviz
Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut
Nov 18, 2025 • Stocktwits
Nuvation Bio (NUVB) Losses Widen 45%—Profit Hopes Challenged Despite Strong Revenue Growth Forecast
Nov 5, 2025 • simplywall.st
Nuvation Bio (NUVB): Losses Worsen, Market Skepticism Endures Despite 51.2% Revenue Growth Forecast
Nov 5, 2025 • Yahoo Finance
Nuvation Bio (NUVB) Is Down 10.1% After Strong IBTROZI Launch Drives Q3 Revenue Surge – What's Changed
Nov 4, 2025 • Yahoo Finance
RBC Capital Maintains Nuvation Bio (NUVB) Outperform Recommendation
Nov 4, 2025 • Nasdaq
Nuvation Bio (NUVB) Q3 2025 Earnings Transcript
Nov 4, 2025 • The Motley Fool
Nuvation Bio’s Earnings Call: IBTROZI’s Success Amid Challenges
Nov 4, 2025 • TipRanks
Nuvation cancels plans to test brain cancer drug directly against Voranigo on FDA's advice
Nov 4, 2025 • Fierce Biotech
Citizens raises Nuvation Bio stock price target to $8 on strong Ibtrozi sales
Nov 4, 2025 • Investing.com
Nuvation Bio backs off from head-to-head brain cancer trial
Nov 4, 2025 • Endpoints News
Earnings call transcript: Nuvation Bio’s Q3 2025 Revenue Surpasses Expectations
Nov 3, 2025 • Investing.com
Nuvation Bio Inc. SEC 10-Q Report
Nov 3, 2025 • TradingView
Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock
Nov 3, 2025 • The Motley Fool
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 3, 2025 • Business Wire
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates
Nov 3, 2025 • Yahoo Finance
Nuvation Bio Inc (NUVB) Q3 2025: Everything You Need To Know Ahead Of Earnings
Oct 31, 2025 • Yahoo Finance
Nuvation Bio (NUVB): Assessing Valuation Following Key Phase 3 Trial Milestone
Oct 25, 2025 • Yahoo Finance
Does Nuvation Bio's (NUVB) Pipeline Progress Highlight Renewed Confidence in Late-Stage Oncology Strategy?
Oct 24, 2025 • simplywall.st
Nuvation Bio enrolls first patient in phase 3 trial for glioma treatment
Oct 23, 2025 • Investing.com
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
Oct 23, 2025 • Business Wire
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
Oct 20, 2025 • Business Wire
Nuvation Bio (NUVB): Assessing Valuation After Key Phase 3 TRUST-IV Trial Milestone
Oct 14, 2025 • simplywall.st
Does Nuvation Bio’s (NUVB) Global Phase 3 Taletrectinib Trial Shift Its Oncology Ambitions?
Oct 12, 2025 • simplywall.st
Nuvation Bio Inc. (NUVB): A Bull Case Theory
Oct 8, 2025 • Insider Monkey
Nuvation Bio Inc. (NUVB): A Bull Case Theory
Oct 8, 2025 • Yahoo Finance
Assessing Nuvation Bio (NUVB) Valuation After Recent Share Price Momentum in the Biotech Sector
Oct 2, 2025 • Yahoo Finance
Nuvation Bio’s Strategic Growth Potential and Promising Pipeline Justify Buy Rating
Sep 30, 2025 • TipRanks
Nuvation issues trial update as Jefferies says buy (NUVB)
Sep 30, 2025 • Seeking Alpha
Jefferies initiates Nuvation Bio stock with Buy rating, $10 price target
Sep 30, 2025 • Investing.com
Jefferies Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation
Sep 30, 2025 • Nasdaq
Why Nuvation Bio Stock Is Skyrocketing Today
Sep 30, 2025 • The Motley Fool
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
Sep 30, 2025 • Business Wire
Nuvation Bio Surges on Japanese Approval of Ibtrozi for Lung Cancer
Sep 28, 2025 • StocksToTrade
Nuvation Bio Soars As Japan Approves Ibtrozi for Advanced Lung Cancer
Sep 27, 2025 • StocksToTrade
Nuvation Bio stock gains as Japan approves IBTROZI for lung cancer
Sep 22, 2025 • Investing.com
Nuvation Bio Inc. (NUVB) IBTROZI Showing Promise in Non-Small Cell Lung Cancer Trials
Sep 20, 2025 • Insider Monkey
Nuvation Bio Says Japan Approves IBTROZI For ROS1+ Advanced Non-small Cell Lung Cancer Treatment
Sep 19, 2025 • Nasdaq
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZI
Sep 19, 2025 • Business Wire
Nuvation Bio bets on Ibtrozi to carve out ROS1 lung cancer market
Sep 18, 2025 • S&P Global
Nuvation Bio Stock: Time to Buy or Sell?
Sep 8, 2025 • timothysykes.com
Nuvation Bio Shines with New Price Target and Bullish Signals
Sep 7, 2025 • timothysykes.com
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
Sep 7, 2025 • Business Wire
Nuvation Bio’s Phase 3 Study on Taletrectinib: A Potential Game-Changer for NSCLC Treatment
Sep 7, 2025 • TipRanks
Nuvation Bio Surges on Analyst Upgrades and Bullish Momentum
Sep 6, 2025 • StocksToTrade
Nuvation Bio Stock Shows Potential with Strategic Developments
Sep 6, 2025 • timothysykes.com
Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug
Sep 5, 2025 • Mugglehead Magazine
Nuvation Bio stock reaches 52-week high at 3.46 USD
Sep 4, 2025 • Investing.com
Is Technical Momentum and Analyst Optimism Reshaping the Investment Case for Nuvation Bio (NUVB)?
Sep 1, 2025 • Yahoo Finance
Why I'm Avoiding Nuvation Bio Despite Its Recent FDA Approval (NYSE:NUVB)
Aug 29, 2025 • Seeking Alpha
Nuvation Bio: What To Expect From IBTROZI Launch? (NYSE:NUVB)
Aug 28, 2025 • Seeking Alpha
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
Aug 27, 2025 • Nasdaq
H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB)
Aug 25, 2025 • Yahoo Finance
Nuvation Bio Inc. (NUVB) Stock Analysis: Unpacking a 171.74% Potential Upside in the Biotech Arena
Aug 15, 2025 • DirectorsTalk Interviews
Transcript : Nuvation Bio Inc., Q2 2025 Earnings Call, Aug 07, 2025
Aug 15, 2025 • MarketScreener
Nuvation Bio’s SWOT analysis: stock poised for growth amid challenges
Aug 14, 2025 • Investing.com
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 7, 2025 • Business Wire
Nuvation Bio’s Milestone with FDA Approval of IBTROZI
Aug 7, 2025 • TipRanks
Earnings call transcript: Nuvation Bio Q2 2025 sees steady EPS, stock rises
Aug 7, 2025 • Investing.com
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Aug 7, 2025 • Yahoo Finance
Nuvation Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Aug 7, 2025 • Reuters
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Aug 5, 2025 • Business Wire
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Aug 5, 2025 • BioSpace
Institutional investors may adopt severe steps after Nuvation Bio Inc.'s (NYSE:NUVB) latest 5.9% drop adds to a year losses
Jul 31, 2025 • Yahoo Finance
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
Jul 24, 2025 • Business Wire
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
Jul 24, 2025 • BioSpace
Nuvation Bio Inc. (NUVB) Stock Analysis: A Biotech With 219.94% Potential Upside
Jul 18, 2025 • DirectorsTalk Interviews
Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits
Jul 13, 2025 • MedCity News
Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring a 210% Potential Upside in the Biotech Sector
Jul 11, 2025 • DirectorsTalk Interviews
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Jul 10, 2025 • PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Jul 10, 2025 • Canada NewsWire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Jul 10, 2025 • prnewswire.co.uk
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy
Jul 9, 2025 • Yahoo Finance
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans
Jun 29, 2025 • Yahoo Finance
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating
Jun 24, 2025 • Yahoo Finance
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
Jun 24, 2025 • Business Wire
Nuvation Bio jumps after insiders purchase shares worth over $1.1M
Jun 20, 2025 • Seeking Alpha
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB)
Jun 18, 2025 • Seeking Alpha
Nuvation Bio price target lowered to $6 from $10 at RBC Capital
Jun 17, 2025 • Investing.com
Nuvation Bio stock holds steady as FDA approves lung cancer drug
Jun 13, 2025 • Investing.com
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug
Jun 12, 2025 • BioSpace
FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Jun 12, 2025 • Pharmaceutical Executive
U.S. FDA Approves Nuvation Bio’s Ibtrozi
Jun 12, 2025 • Contract Pharma
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer
Jun 12, 2025 • PMLiVE
Nuvation Bio stock falls after FDA approves lung cancer drug
Jun 12, 2025 • Investing.com
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC
Jun 12, 2025 • Pharma Letter
FDA clears Nuvation's first product Ibtrozi, for lung cancer
Jun 12, 2025 • pharmaphorum
David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field
Jun 11, 2025 • Fierce Pharma
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib
Jun 11, 2025 • Investing.com
US FDA approves Nuvation Bio's rare lung cancer drug
Jun 11, 2025 • Reuters
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche
Jun 11, 2025 • biopharmadive.com
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro
Jun 11, 2025 • GuruFocus
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Jun 11, 2025 • BioSpace
US FDA approves Nuvation Bio's rare lung cancer drug
Jun 11, 2025 • MarketScreener
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
Jun 11, 2025 • Business Wire
Nuvation Bio Stock Trading Halted, Pending Material News Release
Jun 11, 2025 • MarketScreener